176 related articles for article (PubMed ID: 38206274)
1. Immuno-Oncology Advances in Genitourinary Cancers.
Zang PD; Angeles A; Dorff TB; Pal SK; Gupta S
Am Soc Clin Oncol Educ Book; 2024 Jan; 44(2):e430428. PubMed ID: 38206274
[TBL] [Abstract][Full Text] [Related]
2. Use of immunotherapy in clinical management of genitourinary cancers - a review.
Mar N; Uchio E; Kalebasty AR
Cancer Treat Res Commun; 2022; 31():100564. PubMed ID: 35472699
[TBL] [Abstract][Full Text] [Related]
3. Landscape of Immunotherapy in Genitourinary Malignancies.
Ravindranathan D; Alhalabi O; Rafei H; Shah AY; Bilen MA
Adv Exp Med Biol; 2021; 1342():143-192. PubMed ID: 34972965
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.
Lu K; Chiu KY; Cheng CL
Cancer Treat Res; 2022; 183():201-223. PubMed ID: 35551661
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for genitourinary tumors.
Nakayama T; Kitano S
Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in immuno-oncology and its application to urological cancers.
Mataraza JM; Gotwals P
BJU Int; 2016 Oct; 118(4):506-14. PubMed ID: 27123757
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib plus immunotherapy combinations in metastatic renal cell and urothelial carcinoma.
Meza L; Malhotra J; Favorito C; Pal SK
Future Oncol; 2022 Jan; 18(1):21-33. PubMed ID: 34766841
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder.
Necchi A; Madison R; Raggi D; Jacob JM; Bratslavsky G; Shapiro O; Elvin JA; Vergilio JA; Killian JK; Ngo N; Ramkissoon S; Severson E; Hemmerich AC; Huang R; Ali SM; Chung JH; Reddy P; Miller VA; Schrock AB; Gay LM; Alexander BM; Grivas P; Ross JS
Eur Urol; 2020 Apr; 77(4):548-556. PubMed ID: 31959546
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives].
Bigot F; Bonnet C; Massard C
Bull Cancer; 2017 Apr; 104(4):370-379. PubMed ID: 28237355
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on Geriatric Oncology Research presented at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Shen J; Prentice M; Pollock Y; Franca M; Kanesvaran R
J Geriatr Oncol; 2019 Jul; 10(4):523-525. PubMed ID: 30982753
[No Abstract] [Full Text] [Related]
11. Immunohistochemical Pitfalls in Genitourinary Pathology: 2018 Update.
Cox RM; Magi-Galluzzi C; McKenney JK
Adv Anat Pathol; 2018 Nov; 25(6):387-399. PubMed ID: 30157041
[TBL] [Abstract][Full Text] [Related]
12. The Microbiome and Genitourinary Cancer: A Collaborative Review.
Markowski MC; Boorjian SA; Burton JP; Hahn NM; Ingersoll MA; Maleki Vareki S; Pal SK; Sfanos KS
Eur Urol; 2019 Apr; 75(4):637-646. PubMed ID: 30655087
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in genitourinary malignancies.
Thana M; Wood L
Curr Oncol; 2020 Apr; 27(Suppl 2):S69-S77. PubMed ID: 32368176
[TBL] [Abstract][Full Text] [Related]
14. Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer.
Buti S; Ciccarese C; Iacovelli R; Bersanelli M; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R; Tortora G; Massari F
Future Oncol; 2016 Sep; 12(17):1971-4. PubMed ID: 27312584
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review.
Kato M; Uchida J
Int J Urol; 2023 Dec; 30(12):1068-1077. PubMed ID: 37602512
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
Jang A; Adler DM; Rauterkus GP; Bilen MA; Barata PC
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680214
[TBL] [Abstract][Full Text] [Related]
17. The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk.
Yang Y; Zhang G; Hu C; Luo W; Jiang H; Liu S; Yang H
BMC Urol; 2022 Nov; 22(1):196. PubMed ID: 36451132
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.
Surolia I; Gulley J; Madan RA
Expert Opin Biol Ther; 2014 Dec; 14(12):1769-81. PubMed ID: 25212872
[TBL] [Abstract][Full Text] [Related]
19. Current State of Cell Therapies for Genitourinary Malignancies.
Alkhouli MA; Bazargan S; Pilon-Thomas S; Poch M; Chahoud J
Cancer J; 2022 Jul-Aug 01; 28(4):294-300. PubMed ID: 35880939
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies.
Stühler V; Herrmann L; Maas M; Walz S; Rausch S; Stenzl A; Bedke J
World J Urol; 2022 May; 40(5):1175-1183. PubMed ID: 35217885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]